Veloxis Pharmaceuticals, Inc.

Veloxis Pharmaceuticals, Inc. company information, Employees & Contact Information

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Read our Community Guidelines: https://bit.ly/3FQr7Wg

Company Details

Employees
128
Address
2000 Regency Pkwy,
Phone
45 70 33 33 00
Email
in****@****xis.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cary, North Carolina
Looking for a particular Veloxis Pharmaceuticals, Inc. employee's phone or email?

Veloxis Pharmaceuticals, Inc. Questions

News

Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress - PR Newswire

Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress PR Newswire

Veloxis Pharmaceuticals Receives Approval from USAN for "Pegrizeprument" as Nonproprietary Name for VEL-101 - PR Newswire

Veloxis Pharmaceuticals Receives Approval from USAN for "Pegrizeprument" as Nonproprietary Name for VEL-101 PR Newswire

Veloxis Pharmaceuticals Releases Annual Report for 2018 - GlobeNewswire

Veloxis Pharmaceuticals Releases Annual Report for 2018 GlobeNewswire

Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn - Pharmaceutical Technology

Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn Pharmaceutical Technology

Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression - BioSpace

Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression BioSpace

Veloxis Files Suit Against Accord Healthcare and Intas Pharmaceuticals in Patent Infringement Case - Law Street Media

Veloxis Files Suit Against Accord Healthcare and Intas Pharmaceuticals in Patent Infringement Case Law Street Media

Growing Cary pharma earns key designation to advance transplant drug - The Business Journals

Growing Cary pharma earns key designation to advance transplant drug The Business Journals

Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan

Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package Stock Titan

Asahi Kasei Unveils Deal to Buy Veloxis for $1.3 Billion - Bloomberg.com

Asahi Kasei Unveils Deal to Buy Veloxis for $1.3 Billion Bloomberg.com

Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark - GlobeNewswire

Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark GlobeNewswire

Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas - Fierce Pharma

Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas Fierce Pharma

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn - Pharmaceutical Business review -

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn Pharmaceutical Business review -

Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia - PR Newswire

Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia PR Newswire

CEO on how a Cary company exploded in value: from $200M to $1.3B in two years - The Business Journals

CEO on how a Cary company exploded in value: from $200M to $1.3B in two years The Business Journals

Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics - BioSpace

Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics BioSpace

Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis - GlobeNewswire

Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis GlobeNewswire

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market - PR Newswire

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market PR Newswire

FDA Approves New Indication for ENVARSUS XR® (tacrolimus extended-release tablets) - PR Newswire

FDA Approves New Indication for ENVARSUS XR® (tacrolimus extended-release tablets) PR Newswire

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - PR Newswire

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer PR Newswire

Envarsus XR® to be Subject of Upcoming Presentations at 2019 Am - GuruFocus

Envarsus XR® to be Subject of Upcoming Presentations at 2019 Am GuruFocus

PM360 ANNOUNCES WINNERS OF 2023 PHARMA CHOICE AWARDS - PR Newswire

PM360 ANNOUNCES WINNERS OF 2023 PHARMA CHOICE AWARDS PR Newswire

CEO Collard: How this Cary company's value went from $200M to $800M - The Business Journals

CEO Collard: How this Cary company's value went from $200M to $800M The Business Journals

With new CEO, Cary pharma looks to take on kidney transplant market - The Business Journals

With new CEO, Cary pharma looks to take on kidney transplant market The Business Journals

Top Veloxis Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant